These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33077514)

  • 21. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
    Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.
    Lee JB; Park HS; Choi SJ; Heo SG; An HJ; Kim HR; Hong MH; Lim SM; Chang K; Quinn K; Odegaard J; Shim BY; Cho BC
    Ther Adv Med Oncol; 2022; 14():17588359221141761. PubMed ID: 36544541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C; Thompson JC; Chien AL; Quinn KJ; Hwang WT; Black TA; Yee SS; Christensen TE; LaRiviere MJ; Silva BA; Banks KC; Nagy RJ; Helman E; Berman AT; Ciunci CA; Singh AP; Wasser JS; Bauml JM; Langer CJ; Cohen RB; Carpenter EL
    Clin Cancer Res; 2020 May; 26(10):2354-2361. PubMed ID: 32102950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
    Hsiehchen D; Espinoza M; Valero C; Ahn C; Morris LGT
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
    Nassar AH; Adib E; Abou Alaiwi S; El Zarif T; Groha S; Akl EW; Nuzzo PV; Mouhieddine TH; Perea-Chamblee T; Taraszka K; El-Khoury H; Labban M; Fong C; Arora KS; Labaki C; Xu W; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Zaitlen N; Schoenfeld AJ; Schultz N; Berger MF; MacConaill LE; Ananda G; Kwiatkowski DJ; Choueiri TK; Schrag D; Carrot-Zhang J; Gusev A
    Cancer Cell; 2022 Oct; 40(10):1161-1172.e5. PubMed ID: 36179682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
    Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
    Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
    J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
    Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
    Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
    Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
    Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
    Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
    Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
    Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
    Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
    Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.